SCHEMBL2927261

SCHEMBL2927261

N#C[CH]Cc1ccc(C(F)(F)F)cc1C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.43
ESRRA P11474 3/20 0.39
JAK2 O60674 5/20 0.39
JAK1 P23458 4/20 0.39
TYK2 P29597 3/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CFTR P13569 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 1/20 0.37
RPS6KA3 P51812 1/20 0.37
JAK3 P52333 1/20 0.37
CASP1 P29466 1/20 0.36
POLQ O75417 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
NOTUM Q6P988 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3754934 0.81 MAPK8 (0.39) CES2ALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL5107612 0.80 LCK (0.37) ALDH1A1
SCHEMBL24720949 0.79 JAK2 (0.50) CES2JAK2JAK1TYK2ALDH1A1
SCHEMBL2925555 0.78 CASP1 (0.39) CASP1
SCHEMBL6802462 0.78 ALDH1A1 (0.46) JAK2JAK1TYK2ALDH1A1KDM4E
SCHEMBL15775922 0.75 CES2 (0.42) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6803102 0.75 IKBKB (0.51)
SCHEMBL30738533 0.74 CES2 (0.49) CES2JAK2ALDH1A1KDM4EHPGD
SCHEMBL2921307 0.74 KDM4E (0.41) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL28205058 0.74 CYP3A4 (0.50) CES2JAK2JAK1TYK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225196-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES Merck Frosst Canada Ltd. (CA) 2010-09-08 EP claimed
WO-2009067797-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES MERCK FROSST CANADA LTD. (CA) 2009-06-04 WO claimed
US-8642799-B2 Cysteine protease inhibitors for the treatment of parasitic diseases MERCK CANADA INC. (CA) 2014-02-04 US disclosed
US-20130244962-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES MERCK FROSST CANADA LTD. (CA) 2013-09-19 US disclosed
US-20100305056-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE MERCK FROSST CANADA LTD. (CA) 2010-12-02 US disclosed
EP-2225196-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES Merck Frosst Canada Ltd. (CA) 2010-09-08 EP disclosed
WO-2009067797-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES MERCK FROSST CANADA LTD. (CA) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305056-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE CTSL, SERPINB1, CTSZ CES2 1200/4885ESRRA 4710/4885JAK2 3145/4885
US-20130244962-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES CTSL, SERPINB1, CTSZ CES2 733/4885ESRRA 4724/4885JAK2 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.